DexCom announces new CGM data, direct to Apple Watch functionality in Q2

DexCom (DXCM) announced new clinical evidence supporting the use of Dexcom continuous glucose monitoring, or CGM, for automated insulin delivery, or AID, systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and data will be presented during Dexcom symposia and presentations at the 17th International Conference on Advanced Technologies and Treatments for Diabetes, held March 6-9, in Florence. Dexcom announced that ‘direct to Apple (AAPL) Watch’ functionality for Apple Watch will have a phased launch available to all G7 iOS users everywhere by the end of the second quarter of this year. The announcement means that Dexcom G7 will soon be the only CGM system that can connect directly to Apple Watch without always needing to carry an iPhone. People choosing Dexcom G7 to help manage their diabetes will have access to ‘direct to Apple Watch’ as soon as it launches in their country. Data from the longest prospective follow-up study to date of a cohort with established Type 1 diabetes, using the Insulet Omnipod 5 automated insulin delivery system with Dexcom G6, showed that long-term use of the AID system could safely maintain improvements in glycaemic outcomes for up to two years. Perhaps most significantly, despite the long duration of the study, event rates for severe hypoglycaemia and diabetic ketoacidosis remained low at 2.04 and 0.24 events per 100 person-years. Furthermore, real-world evidence from almost 3,000 people using a Tandem Control-IQ AID system, powered by Dexcom CGM, demonstrated lower rates for both severe hypoglycaemia and diabetic ketoacidosis over 12 months compared to historic rates. Concurrent with these lower rates, on average adult participants spent more than 70% CGM time in range, while paediatric participants achieved 60% CGM time in range. Dexcom also announced the availability, in the USA, of Dexcom G6 with Tandem Mobi, the world’s smallest, durable automated insulin delivery system++. Integration with Dexcom G7 will quickly follow in the USA in the second quarter of this year. As demonstrated in multiple symposia and presentations at ATTD this year, clinical evidence continues to build demonstrating the effectiveness of Dexcom CGM use amongst people with all types of diabetes. Of particular note, Dexcom announced a first-of-its-kind study directly linking the benefits of CGM with a reduction in mortality for people treating Type 1 or Type 2 diabetes with insulin. These results indicate use of CGM may have broad-based benefits that extend beyond glucose lowering in patients with diabetes on insulin. Dexcom also unveiled new global user data analysis showing clinically meaningful reduction in HbA1c specifically for people managing their Type 2 diabetes with a GLP1 and using a CGM sensor compared to groups not using CGM. Dexcom data also showed that amongst Type 2 user populations, the more regularly a Dexcom CGM was worn, the more time a user spent within their desired glucose range. Furthermore, a qualitative study involving people treating their Type 2 diabetes with basal insulin found the visualization of glucose levels offered by Dexcom CGM improved understanding of the impact of treatment and lifestyle decisions on glucose levels, and the impact of those glucose levels on additional health issues.